Text Size

SSNB in Hemiplegic Shoulder Pain

This study has been completed.
Sponsor:
Information provided by:
Chulalongkorn University
ClinicalTrials.gov Identifier:
NCT00732589
First received: August 8, 2008
Last updated: November 17, 2009
Last verified: August 2008
History of Changes
  Purpose

The purpose of this study is to compare suprascapular nerve block with therapeutic ultrasound in stroke patients who have shoulder pain in weak side.


Condition Intervention Phase
Shoulder Pain
Stroke
 Drug: 1% xylocaine
Other: ultrasound
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Suprascapular Nerve Block in Hemiplegic Shoulder Pain.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Chulalongkorn University:

Primary Outcome Measures:
  • VAS score of pain [ Time Frame: 4 weeks after intervention ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Range of motion of the shoulder joint [ Time Frame: 4 weeks after intervention ] [ Designated as safety issue: No ]

Estimated Enrollment: 0
Study Start Date: August 2008
Study Completion Date: May 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Suprascapular nerve block
 Drug: 1% xylocaine
10 cc. of 1%xylocaine, once a week
Other Name: suprascapular nerve block
Experimental: B
therapeutic ultrasound
 Other: ultrasound
ultrasound at shoulder area about 10 mins.
Other Name: therapeutic ultrasound

Detailed Description:

Shoulder pain is a common complication after a cerebrovascular accident.Hemiplegic shoulder pain has been shown to affect stroke outcome in a negative way.It interferes with recovery after stroke:it can cause distress and reduced activities and can markedly hinder rehabilitation.Suprascapular nerve block has been shown to be effective as an analgesic for different indications such as shoulder capsulitis.The purpose of this study was to evaluate the effectiveness of this technique conjunction with a rehabilitation program to reduce shoulder pain in hemiplegic patients.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stroke patients who develope shoulder pain at weak limb.
  • Good conscious and able to access pain score.
  • No history of drug reaction with xylocaine
  • No history of fracture,tumor or blood tendency.
  • Willing to enrolled to study and signs inform consent.

Exclusion Criteria:

  • Patients who do not meet the inclusion criteria.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00732589

Locations
Thailand
Department of physical medicine and rehabilitation, Faculty of medicien, Chulalongkorn University
Bangkok, Thailand
Sponsors and Collaborators
Chulalongkorn University
Investigators
Principal Investigator: Jariya Boonhong, physiatist Unaffiliation
  More Information

No publications provided

Responsible Party: Jariya Boonhong/ Department of Rehabilitation Medicine, Faculty of Medicine, Chulalongkorn University, Chulalongkorn University
ClinicalTrials.gov Identifier: NCT00732589     History of Changes
Other Study ID Numbers: Chulalongkorn University
Study First Received: August 8, 2008
Last Updated: November 17, 2009
Health Authority: Thailand: Food and Drug Administration

Keywords provided by Chulalongkorn University:
suprascapular nerve block
shoulder pain
hemiplegia

Additional relevant MeSH terms:
Shoulder Pain
Stroke
Arthralgia
Joint Diseases
Musculoskeletal Diseases
Pain
Signs and Symptoms
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
 Lidocaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Anti-Arrhythmia Agents
Cardiovascular Agents

ClinicalTrials.gov processed this record on May 16, 2013